Bibek Gyanwali
Research Subjects
Bibek Gyanwali has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Saima Hilal
National University of Singapore
7 shared publications - Christopher Chen
Department of Pharmacology Yong Loo Lin School of Medicine National University of Singapore Singapore Singapore
6 shared publications - Henri A. Vrooman
Erasmus Medical Ctr. (Netherlands)
3 shared publications - Arthur Mark Richards
Cardiovascular Research Institute, National University Health System, Singapore 117599, Singapore
2 shared publications - Chuen Seng Tan
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore
2 shared publications - Henri J. M. M. Mutsaerts
Amsterdam UMC
2 shared publications
Latest Publications
- Open Access
- 21 October 2026
- Published by Wiley in Clinical and Experimental Neuroimmunology
- Vol. 17 (4)
Patient‐Journey Mapping of CIDP Management in the Philippines: A Survey‐Informed Expert Panel Study and Recommendations From Treat CIDP Philippine Working Group
Objectives: To characterize real‐world barriers to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) management in the Philippines and identify pragmatic patient‐centered solutions aligned with international guidance and local health‐system realities. Methods: We conducted a survey‐informed qualitative expert‐panel study involving six Philippine neurologists from public and private tertiary centers. Data sources included review of EAN/PNS‐2021 CIDP guidelines, contemporary literature, and pre‐meeting survey results on local clinical practice followed by structured discussions. Findings were organized using a patient‐journey framework and analyzed thematically across clinical, operational, policy, and economic domains. Results: Real‐world challenges were identified across three domains. Clinical: clinical mimics, variability in electrodiagnostic interpretation, limited test availability, and delayed referral; Operational: partial or variable treatment response, corticosteroid side‐effects, inpatient infusion logistics, and difficulties maintaining therapy; and Policy/economic: high out‐of‐pocket costs, limited reimbursement, procurement delays, and regional inequities. Experts described several key components of patient‐centered CIDP care, including the use of standardized diagnostic pathways, improved access to neurophysiological testing, increased disease awareness, and structured monitoring using disability and impairment scales. Additional elements included the incorporation of patient‐reported outcomes, shared decision‐making, and individualized infusion and weaning strategies, and generation of local real‐world, cost‐effectiveness, budget‐impact, and patient‐reported outcome data. Conclusions: This study identifies neurologist‐perceived clinical and system barriers affecting CIDP care across the patient journey in the Philippines. Findings support implementation of an evidence‐based patient‐centered framework aligned with international guidelines but adapted for the Philippine healthcare system. Such a framework may improve diagnosis, streamline treatment, and enhance equitable access.
- 21 October 2026
- Published by Wiley in Clinical and Experimental Neuroimmunology
- Vol. 17 (4)
Open AccessPatient‐Journey Mapping of CIDP Management in the Philippines: A Survey‐Informed Expert Panel Study and Recommendations From Treat CIDP Philippine Working Group
Objectives: To characterize real‐world barriers to chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) management in the Philippines and identify pragmatic patient‐centered solutions aligned with international guidance and local health‐system realities. Methods: We conducted a survey‐informed qualitative expert‐panel study involving six Philippine neurologists from public and private tertiary centers. Data sources included review of EAN/PNS‐2021 CIDP guidelines, contemporary literature, and pre‐meeting survey results on local clinical practice followed by structured discussions. Findings were organized using a patient‐journey framework and analyzed thematically across clinical, operational, policy, and economic domains. Results: Real‐world challenges were identified across three domains. Clinical: clinical mimics, variability in electrodiagnostic interpretation, limited test availability, and delayed referral; Operational: partial or variable treatment response, corticosteroid side‐effects, inpatient infusion logistics, and difficulties maintaining therapy; and Policy/economic: high out‐of‐pocket costs, limited reimbursement, procurement delays, and regional inequities. Experts described several key components of patient‐centered CIDP care, including the use of standardized diagnostic pathways, improved access to neurophysiological testing, increased disease awareness, and structured monitoring using disability and impairment scales. Additional elements included the incorporation of patient‐reported outcomes, shared decision‐making, and individualized infusion and weaning strategies, and generation of local real‐world, cost‐effectiveness, budget‐impact, and patient‐reported outcome data. Conclusions: This study identifies neurologist‐perceived clinical and system barriers affecting CIDP care across the patient journey in the Philippines. Findings support implementation of an evidence‐based patient‐centered framework aligned with international guidelines but adapted for the Philippine healthcare system. Such a framework may improve diagnosis, streamline treatment, and enhance equitable access.
- Open Access
Real-world usage pattern, effectiveness and safety of oral tramadol/dexketoprofen trometamol fixed-dose combination in moderate-to-severe acute pain in Asia: a prospective, multicentre, observational study
Objectives This study aims to determine the usage pattern, effectiveness and safety of oral tramadol 75 mg and dexketoprofen trometamol 25 mg fixed-dose combination (TRAM/DKP FDC) in the short-term treatment of moderate-to-severe acute pain in real-world clinical practice in Asia. Design Real-world, prospective, multicentre, observational, phase IV study. Setting 13 tertiary-care hospital sites across the Philippines, Thailand, Malaysia and Singapore. Participants Adult patients aged 18–80 years prescribed TRAM/DKP FDC for the short-term (up to 5 days) treatment of moderate-to-severe acute pain. Main outcome measures Primary endpoints were the proportion of patients prescribed TRAM/DKP FDC with different types of postsurgical and non-surgical treatments, and the average dosing frequency and duration of TRAM/DKP FDC treatment. Secondary endpoints were the proportion of patients achieving ≥30% pain reduction at 8 hours post the first dose (pain severity was assessed using the 11-point Numeric Pain Rating Scale); patient satisfaction at the end of treatment (based on a 5-point Patient Global Evaluation Scale (PGE)) and safety including the incidence of adverse drug reactions (ADRs). Results Among 599 patients (median age 44 years, 61.3% female) enrolled in this study, 68.61% (n=411) were postsurgical and 31.39% (n=188) were non-surgical patients. TRAM/DKP FDC was prescribed in a diverse group of postsurgical patients (eg, orthopaedic, general and cancer surgery) as well as in non-surgical conditions (eg, lower back pain and musculoskeletal pain). In the majority of patients, TRAM/DKP FDC was prescribed every 8 hours (65.94%) and for 5 days (78.80%). There was a significant reduction in pain intensity throughout the study and 65% of patients achieved ≥30% pain reduction from baseline at 8 hours post the first dose of TRAM/DKP FDC on day 1. 95.69% of patients were satisfied with the treatment (rated good, very good and excellent on the PGE scale). Overall, 13.9% of patients reported ADRs; most were mild to moderate in severity. The most common ADRs were nausea, vomiting and dizziness. Conclusion This study showed that TRAM/DKP FDC was used in diverse types of postsurgical and non-surgical patients in the real-world setting in Asia. It effectively reduced pain and was well tolerated with a high level of patient satisfaction.
Open AccessReal-world usage pattern, effectiveness and safety of oral tramadol/dexketoprofen trometamol fixed-dose combination in moderate-to-severe acute pain in Asia: a prospective, multicentre, observational study
Objectives This study aims to determine the usage pattern, effectiveness and safety of oral tramadol 75 mg and dexketoprofen trometamol 25 mg fixed-dose combination (TRAM/DKP FDC) in the short-term treatment of moderate-to-severe acute pain in real-world clinical practice in Asia. Design Real-world, prospective, multicentre, observational, phase IV study. Setting 13 tertiary-care hospital sites across the Philippines, Thailand, Malaysia and Singapore. Participants Adult patients aged 18–80 years prescribed TRAM/DKP FDC for the short-term (up to 5 days) treatment of moderate-to-severe acute pain. Main outcome measures Primary endpoints were the proportion of patients prescribed TRAM/DKP FDC with different types of postsurgical and non-surgical treatments, and the average dosing frequency and duration of TRAM/DKP FDC treatment. Secondary endpoints were the proportion of patients achieving ≥30% pain reduction at 8 hours post the first dose (pain severity was assessed using the 11-point Numeric Pain Rating Scale); patient satisfaction at the end of treatment (based on a 5-point Patient Global Evaluation Scale (PGE)) and safety including the incidence of adverse drug reactions (ADRs). Results Among 599 patients (median age 44 years, 61.3% female) enrolled in this study, 68.61% (n=411) were postsurgical and 31.39% (n=188) were non-surgical patients. TRAM/DKP FDC was prescribed in a diverse group of postsurgical patients (eg, orthopaedic, general and cancer surgery) as well as in non-surgical conditions (eg, lower back pain and musculoskeletal pain). In the majority of patients, TRAM/DKP FDC was prescribed every 8 hours (65.94%) and for 5 days (78.80%). There was a significant reduction in pain intensity throughout the study and 65% of patients achieved ≥30% pain reduction from baseline at 8 hours post the first dose of TRAM/DKP FDC on day 1. 95.69% of patients were satisfied with the treatment (rated good, very good and excellent on the PGE scale). Overall, 13.9% of patients reported ADRs; most were mild to moderate in severity. The most common ADRs were nausea, vomiting and dizziness. Conclusion This study showed that TRAM/DKP FDC was used in diverse types of postsurgical and non-surgical patients in the real-world setting in Asia. It effectively reduced pain and was well tolerated with a high level of patient satisfaction.
- Open Access
REKOVER study protocol: a pRospective patient treatment rEgistry of tramadol and dexKetoprofen trometamol oral fixed-dose combination (SKUDEXA) in mOderate to seVere acutE pain in Real-world setting in Asia
Introduction Satisfactory management of acute pain remains a major medical challenge despite the availability of multiple therapeutic options including the fixed-dose combination (FDC) drugs. Tramadol and dexketoprofen trometamol (TRAM/DKP) 75/25 mg FDC was launched in 2018 in Asia and is widely used in the management of moderate to severe acute pain. There are limited data on its effectiveness and safety in Asian patients, and therefore, a need to better understand its usage patterns in clinical practice. We aim to understand the usage pattern of TRAM/DKP FDC, its effectiveness and tolerability in patients with moderate to severe acute pain in Asia. Methods and analysis REKOVER is a phase-IV, multicountry, multicentre, prospective, real-world observational study. A total of 750 postsurgical and non-surgical patients (male and female, aged 18–80 years) will be recruited from 13 tertiary-care hospitals (15 sites) in Singapore, Thailand, the Philippines and Malaysia. All patients prescribed with TRAM/DKP FDC and willing to participate in the study will be enrolled. The recruitment duration for each site will be 6 months. The severity of pain will be collected using Numeric Pain Rating Scale through the treatment period from day 1 to day 5, while satisfaction with the treatment will be evaluated using Patient Global Evaluation Scale at the end of treatment. Any adverse event reported during the study duration will be recorded for safety analysis (up to day 6). The study data will be entered into the ClaimIt portal and mobile application (app) (ObvioHealth, USA). All the inpatient data will be entered into the portal by the study site and for outpatient it will be done by patients through an app. Ethics and dissemination The study has been approved by the local ethics committee from each study sites in Singapore, Thailand, the Philippines and Malaysia. Findings will be disseminated through local and global conference presentations, publications in peer-reviewed scientific journals and continuing medical education.
Open AccessREKOVER study protocol: a pRospective patient treatment rEgistry of tramadol and dexKetoprofen trometamol oral fixed-dose combination (SKUDEXA) in mOderate to seVere acutE pain in Real-world setting in Asia
Introduction Satisfactory management of acute pain remains a major medical challenge despite the availability of multiple therapeutic options including the fixed-dose combination (FDC) drugs. Tramadol and dexketoprofen trometamol (TRAM/DKP) 75/25 mg FDC was launched in 2018 in Asia and is widely used in the management of moderate to severe acute pain. There are limited data on its effectiveness and safety in Asian patients, and therefore, a need to better understand its usage patterns in clinical practice. We aim to understand the usage pattern of TRAM/DKP FDC, its effectiveness and tolerability in patients with moderate to severe acute pain in Asia. Methods and analysis REKOVER is a phase-IV, multicountry, multicentre, prospective, real-world observational study. A total of 750 postsurgical and non-surgical patients (male and female, aged 18–80 years) will be recruited from 13 tertiary-care hospitals (15 sites) in Singapore, Thailand, the Philippines and Malaysia. All patients prescribed with TRAM/DKP FDC and willing to participate in the study will be enrolled. The recruitment duration for each site will be 6 months. The severity of pain will be collected using Numeric Pain Rating Scale through the treatment period from day 1 to day 5, while satisfaction with the treatment will be evaluated using Patient Global Evaluation Scale at the end of treatment. Any adverse event reported during the study duration will be recorded for safety analysis (up to day 6). The study data will be entered into the ClaimIt portal and mobile application (app) (ObvioHealth, USA). All the inpatient data will be entered into the portal by the study site and for outpatient it will be done by patients through an app. Ethics and dissemination The study has been approved by the local ethics committee from each study sites in Singapore, Thailand, the Philippines and Malaysia. Findings will be disseminated through local and global conference presentations, publications in peer-reviewed scientific journals and continuing medical education.
- Open Access
- 6 December 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (23)
Effects of Carotid Artery Stiffness on Cerebral Small‐Vessel Disease and Cognition
Background: Carotid artery stiffness is associated with cognitive impairment and dementia, but the underlying mechanisms remain unknown. We examined the associations of carotid artery stiffness with cerebral small‐vessel disease markers, cognition, and dementia subtypes in a memory clinic cohort. Methods and Results: A total of 272 participants underwent carotid ultrasonography, 3 Tesla brain magnetic resonance imaging, and neuropsychological assessment. Carotid ultrasonography was used to assess β‐index, pressure‐strain elastic modulus, and pulse‐wave velocity‐β. Brain magnetic resonance images were graded for cerebral small‐vessel disease markers, including white matter hyperintensities, lacunes, and cerebral microbleeds. Participants were classified as having no cognitive impairment, cognitive impairment and no dementia, or dementia subtyped as Alzheimer disease and vascular dementia. Cognition was assessed using National Institute of Neurological Disorders and Stroke–Canadian Stroke Network harmonization battery. After adjusting for age, sex, cardiovascular risk factors, and diseases, multivariable models showed that β‐index ( β =0.69; P =0.002), elastic modulus ( β =0.78; P β =0.80; P <0.001) were associated with white matter hyperintensities, and elastic modulus (odds ratio [OR], 1.39 [95% CI, 1.04–1.85]) and pulse‐wave velocity‐β (OR, 1.47 [95% CI, 1.10–1.98]) were independently associated with lacunes. Similarly, β‐index (OR, 2.04 [95% CI, 1.14–4.13]), elastic modulus (OR, 2.22 [95% CI, 1.25–4.42]), and pulse‐wave velocity‐β (OR, 2.50 [95% CI, 1.36–5.18]) were independently associated with vascular dementia. Carotid stiffness measures were independently associated with worse performance in global cognition, visuomotor speed, visuospatial function, and executive function. These associations became largely nonsignificant after further adjusting for cerebral small‐vessel disease markers. Conclusions: In memory clinic patients, carotid artery stiffness was associated with white matter hyperintensities and lacunes, impairment in global and domain‐specific cognition, and causative subtypes of dementia, particularly vascular. The effects of carotid stiffness on cognition were not independent of, and were partially mediated by, cerebral small‐vessel disease.
- 6 December 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (23)
Open AccessEffects of Carotid Artery Stiffness on Cerebral Small‐Vessel Disease and Cognition
Background: Carotid artery stiffness is associated with cognitive impairment and dementia, but the underlying mechanisms remain unknown. We examined the associations of carotid artery stiffness with cerebral small‐vessel disease markers, cognition, and dementia subtypes in a memory clinic cohort. Methods and Results: A total of 272 participants underwent carotid ultrasonography, 3 Tesla brain magnetic resonance imaging, and neuropsychological assessment. Carotid ultrasonography was used to assess β‐index, pressure‐strain elastic modulus, and pulse‐wave velocity‐β. Brain magnetic resonance images were graded for cerebral small‐vessel disease markers, including white matter hyperintensities, lacunes, and cerebral microbleeds. Participants were classified as having no cognitive impairment, cognitive impairment and no dementia, or dementia subtyped as Alzheimer disease and vascular dementia. Cognition was assessed using National Institute of Neurological Disorders and Stroke–Canadian Stroke Network harmonization battery. After adjusting for age, sex, cardiovascular risk factors, and diseases, multivariable models showed that β‐index ( β =0.69; P =0.002), elastic modulus ( β =0.78; P β =0.80; P <0.001) were associated with white matter hyperintensities, and elastic modulus (odds ratio [OR], 1.39 [95% CI, 1.04–1.85]) and pulse‐wave velocity‐β (OR, 1.47 [95% CI, 1.10–1.98]) were independently associated with lacunes. Similarly, β‐index (OR, 2.04 [95% CI, 1.14–4.13]), elastic modulus (OR, 2.22 [95% CI, 1.25–4.42]), and pulse‐wave velocity‐β (OR, 2.50 [95% CI, 1.36–5.18]) were independently associated with vascular dementia. Carotid stiffness measures were independently associated with worse performance in global cognition, visuomotor speed, visuospatial function, and executive function. These associations became largely nonsignificant after further adjusting for cerebral small‐vessel disease markers. Conclusions: In memory clinic patients, carotid artery stiffness was associated with white matter hyperintensities and lacunes, impairment in global and domain‐specific cognition, and causative subtypes of dementia, particularly vascular. The effects of carotid stiffness on cognition were not independent of, and were partially mediated by, cerebral small‐vessel disease.
- 8 September 2022
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43 (10) , 1418-1423
Arterial Spin-Labeling Parameters and Their Associations with Risk Factors, Cerebral Small-Vessel Disease, and Etiologic Subtypes of Cognitive Impairment and Dementia
BACKGROUND AND PURPOSE: Cerebral small-vessel disease may alter cerebral blood flow (CBF) leading to brain changes and, hence, cognitive impairment and dementia. CBF and the spatial coefficient of variation can be measured quantitatively by arterial spin-labeling. We aimed to investigate the associations of demographics, vascular risk factors, location, and severity of cerebral small-vessel disease as well as the etiologic subtypes of cognitive impairment and dementia with CBF and the spatial coefficient of variation. MATERIALS AND METHODS: Three hundred ninety patients with a diagnosis of no cognitive impairment, cognitive impairment no dementia, vascular cognitive impairment no dementia, Alzheimer disease, and vascular dementia were recruited from the memory clinic. Cerebral microbleeds and lacunes were categorized into strictly lobar, strictly deep, and mixed-location and enlarged perivascular spaces into the centrum semiovale and basal ganglia. Total and region-specific white matter hyperintensity volumes were segmented using FreeSurfer. CBF (n = 333) and the spatial coefficient of variation (n = 390) were analyzed with ExploreASL from 2D-EPI pseudocontinuous arterial spin-labeling images in white matter (WM) and gray matter (GM). To analyze the effect of demographic and vascular risk factors as well as the location and severity of cerebral small-vessel disease markers on arterial spin-labeling parameters, we constructed linear regression models, whereas logistic regression models were used to determine the association between arterial spin-labeling parameters and cognitive impairment no dementia, vascular cognitive impairment no dementia, Alzheimer disease, and vascular dementia. RESULTS: Increasing age, male sex, hypertension, hyperlipidemia, history of heart disease, and smoking were associated with lower CBF and a higher spatial coefficient of variation. Higher numbers of lacunes and cerebral microbleeds were associated with lower CBF and a higher spatial coefficient of variation. Location-specific analysis showed mixed-location lacunes and cerebral microbleeds were associated with lower CBF. Higher total, anterior, and posterior white matter hyperintensity volumes were associated with a higher spatial coefficient of variation. No association was observed between enlarged perivascular spaces and arterial spin-labeling parameters. A higher spatial coefficient of variation was associated with the diagnosis of vascular cognitive impairment no dementia, Alzheimer’s disease, and vascular dementia. CONCLUSIONS: Reduced CBF and an increased spatial coefficient of variation were associated with cerebral small-vessel disease, and more specifically lacunes, whereas cerebral microbleeds and white matter hyperintensities were associated with WM-CBF and GM spatial coefficient of variation. The spatial coefficient of variation was associated with cognitive impairment and dementia, suggesting that hypoperfusion might be the key underlying mechanism for vascular brain damage.
- 8 September 2022
- Published by American Society of Neuroradiology (ASNR) in American Journal of Neuroradiology
- Vol. 43 (10) , 1418-1423
Arterial Spin-Labeling Parameters and Their Associations with Risk Factors, Cerebral Small-Vessel Disease, and Etiologic Subtypes of Cognitive Impairment and Dementia
BACKGROUND AND PURPOSE: Cerebral small-vessel disease may alter cerebral blood flow (CBF) leading to brain changes and, hence, cognitive impairment and dementia. CBF and the spatial coefficient of variation can be measured quantitatively by arterial spin-labeling. We aimed to investigate the associations of demographics, vascular risk factors, location, and severity of cerebral small-vessel disease as well as the etiologic subtypes of cognitive impairment and dementia with CBF and the spatial coefficient of variation. MATERIALS AND METHODS: Three hundred ninety patients with a diagnosis of no cognitive impairment, cognitive impairment no dementia, vascular cognitive impairment no dementia, Alzheimer disease, and vascular dementia were recruited from the memory clinic. Cerebral microbleeds and lacunes were categorized into strictly lobar, strictly deep, and mixed-location and enlarged perivascular spaces into the centrum semiovale and basal ganglia. Total and region-specific white matter hyperintensity volumes were segmented using FreeSurfer. CBF (n = 333) and the spatial coefficient of variation (n = 390) were analyzed with ExploreASL from 2D-EPI pseudocontinuous arterial spin-labeling images in white matter (WM) and gray matter (GM). To analyze the effect of demographic and vascular risk factors as well as the location and severity of cerebral small-vessel disease markers on arterial spin-labeling parameters, we constructed linear regression models, whereas logistic regression models were used to determine the association between arterial spin-labeling parameters and cognitive impairment no dementia, vascular cognitive impairment no dementia, Alzheimer disease, and vascular dementia. RESULTS: Increasing age, male sex, hypertension, hyperlipidemia, history of heart disease, and smoking were associated with lower CBF and a higher spatial coefficient of variation. Higher numbers of lacunes and cerebral microbleeds were associated with lower CBF and a higher spatial coefficient of variation. Location-specific analysis showed mixed-location lacunes and cerebral microbleeds were associated with lower CBF. Higher total, anterior, and posterior white matter hyperintensity volumes were associated with a higher spatial coefficient of variation. No association was observed between enlarged perivascular spaces and arterial spin-labeling parameters. A higher spatial coefficient of variation was associated with the diagnosis of vascular cognitive impairment no dementia, Alzheimer’s disease, and vascular dementia. CONCLUSIONS: Reduced CBF and an increased spatial coefficient of variation were associated with cerebral small-vessel disease, and more specifically lacunes, whereas cerebral microbleeds and white matter hyperintensities were associated with WM-CBF and GM spatial coefficient of variation. The spatial coefficient of variation was associated with cognitive impairment and dementia, suggesting that hypoperfusion might be the key underlying mechanism for vascular brain damage.
- 1 February 2022
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 33 (2) , 136-146
Alpha-Ketoglutarate dietary supplementation to improve health in humans
- 1 February 2022
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 33 (2) , 136-146
Alpha-Ketoglutarate dietary supplementation to improve health in humans
- 1 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S4)
Determinants of arterial spin labeling parameters and its association with cerebral small vessel disease and diagnostic groups
Background: Cerebral small vessel disease (SVD) may alter cerebral blood flow (CBF) leading to brain changes and hence cognitive impairment and dementia in elderly. CBF and spatial coefficient of variation (sCoV) can be measured quantitatively by Arterial Spin Labelling (ASL). CBF and sCoV have been related to age and systemic vascular risk factors. The relation of CBF and sCoV with location and severity of SVD and etiologic subtypes of cognitive impairment and dementia have not been explored in detail. We aim to investigate the association of demographic, vascular risk factors, location and severity of SVD with ASL parameters. We further investigate the association of ASL parameters with etiologic subtypes of cognitive impairment and dementia in a memory clinic population.Method: We included 390 subjects (median: 73 11years, women = 52.3%) from an ongoing memory‐clinic based case‐control study. Patients were classified as no cognitive impairment, cognitive impairment no dementia (CIND), vascular CIND (VCIND) and dementia [Alzheimer’s disease (AD) and Vascular Dementia (VaD)]. Cerebral microbleeds (CMBs) and lacunes were categorized into strictly lobar, strictly deep and mixed‐location; ePVS into centrum semiovale and basal ganglia. Total and region‐specific white matter hyperintensities (WMH) volumes were automatically segmented using a validated pipeline. sCoV and CBF were analyzed with ExploreASL from 2D‐EPI pseudo‐continuous ASL images.Result: Increasing age, male sex, hypertension, hyperlipidemia, history of heart disease and smoking were associated with CBF and sCoV. Increasing numbers of lacunes and CMBs were associated with reduced CBF and increased sCoV. Location‐specific analysis showed mixed‐location lacunes and CMBs were associated with hypoperfusion. Total WMH volume was associated with associated with increased sCoV. Region specific analysis with anterior and posterior WMH volumes showed similar results. No association was observed between ePVS and ASL parameters. Increased sCoV was associated with the diagnosis of VCIND, AD and VaD.Conclusion: Increased sCoV in ASL is associated with SVD, cognitive impairment and dementia, suggesting that SVD may induce brain changes via vascular insufficiency. Thus future research aimed to elucidate the pathophysiology of SVD and vascular insufficiency in elderly may help in developing prevention and treatment strategies.
- 1 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S4)
Determinants of arterial spin labeling parameters and its association with cerebral small vessel disease and diagnostic groups
Background: Cerebral small vessel disease (SVD) may alter cerebral blood flow (CBF) leading to brain changes and hence cognitive impairment and dementia in elderly. CBF and spatial coefficient of variation (sCoV) can be measured quantitatively by Arterial Spin Labelling (ASL). CBF and sCoV have been related to age and systemic vascular risk factors. The relation of CBF and sCoV with location and severity of SVD and etiologic subtypes of cognitive impairment and dementia have not been explored in detail. We aim to investigate the association of demographic, vascular risk factors, location and severity of SVD with ASL parameters. We further investigate the association of ASL parameters with etiologic subtypes of cognitive impairment and dementia in a memory clinic population.Method: We included 390 subjects (median: 73 11years, women = 52.3%) from an ongoing memory‐clinic based case‐control study. Patients were classified as no cognitive impairment, cognitive impairment no dementia (CIND), vascular CIND (VCIND) and dementia [Alzheimer’s disease (AD) and Vascular Dementia (VaD)]. Cerebral microbleeds (CMBs) and lacunes were categorized into strictly lobar, strictly deep and mixed‐location; ePVS into centrum semiovale and basal ganglia. Total and region‐specific white matter hyperintensities (WMH) volumes were automatically segmented using a validated pipeline. sCoV and CBF were analyzed with ExploreASL from 2D‐EPI pseudo‐continuous ASL images.Result: Increasing age, male sex, hypertension, hyperlipidemia, history of heart disease and smoking were associated with CBF and sCoV. Increasing numbers of lacunes and CMBs were associated with reduced CBF and increased sCoV. Location‐specific analysis showed mixed‐location lacunes and CMBs were associated with hypoperfusion. Total WMH volume was associated with associated with increased sCoV. Region specific analysis with anterior and posterior WMH volumes showed similar results. No association was observed between ePVS and ASL parameters. Increased sCoV was associated with the diagnosis of VCIND, AD and VaD.Conclusion: Increased sCoV in ASL is associated with SVD, cognitive impairment and dementia, suggesting that SVD may induce brain changes via vascular insufficiency. Thus future research aimed to elucidate the pathophysiology of SVD and vascular insufficiency in elderly may help in developing prevention and treatment strategies.
- 1 September 2021
- Published by Elsevier in Neurochemistry International
- Vol. 148, 105073
Cerebral microbleeds in vascular dementia from clinical aspects to host-microbial interaction
- 1 September 2021
- Published by Elsevier in Neurochemistry International
- Vol. 148, 105073
Cerebral microbleeds in vascular dementia from clinical aspects to host-microbial interaction
- 21 July 2021
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 82 (2) , 561-573
The Effects of Mean of Visit-to-Visit Blood Pressure on Incident Brain Vascular Lesions and Functional-Cognitive Decline
Background: Cerebrovascular disease (CeVD) is an underlying cause of cognitive impairment and dementia. Hypertension is a known risk factor of CeVD, but the effects of mean of visit-to-visit blood pressure (BP) on incident CeVD and functional-cognitive decline remains unclear. Objective: To determine the association between mean of visit-to-visit BP with the incidence and progression of CeVD [white matter hyperintensities (WMH), infarcts (cortical infarcts and lacunes), cerebral microbleeds (CMBs), intracranial stenosis, and hippocampal volume] as well as functional-cognitive decline over 2 years of follow-up. Methods: 373 patients from a memory-clinic underwent BP measurements at baseline, year 1, and year 2. The mean of visit-to-visit systolic BP, diastolic BP, pulse pressure, and mean arterial pressure were calculated. Baseline and year 2 MRI scans were graded for WMH, infarcts, CMBs, intracranial stenosis, and hippocampal volume. Functional-cognitive decline was assessed using locally validated protocol. Logistic and linear regression models with odds ratios, mean difference, and 95%confidence interval were constructed to analyze associations of visit-to-visit BP on CeVD incidence and progression as well as functional-cognitive decline. Results: Higher mean of visit-to-visit diastolic BP was associated with WMH progression. Higher tertiles of diastolic BP was associated with WMH progression and incident CMBs. There was no association between mean of visit-to-visit BP measures with incident cerebral infarcts, intracranial stenosis, change in hippocampal volume, and functional-cognitive decline. Conclusion: These findings suggest the possibility of hypertension-related vascular brain damage. Careful monitoring and management of BP in elderly patients is essential to reduce the incidence and progression of CeVD.
- 21 July 2021
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 82 (2) , 561-573
The Effects of Mean of Visit-to-Visit Blood Pressure on Incident Brain Vascular Lesions and Functional-Cognitive Decline
Background: Cerebrovascular disease (CeVD) is an underlying cause of cognitive impairment and dementia. Hypertension is a known risk factor of CeVD, but the effects of mean of visit-to-visit blood pressure (BP) on incident CeVD and functional-cognitive decline remains unclear. Objective: To determine the association between mean of visit-to-visit BP with the incidence and progression of CeVD [white matter hyperintensities (WMH), infarcts (cortical infarcts and lacunes), cerebral microbleeds (CMBs), intracranial stenosis, and hippocampal volume] as well as functional-cognitive decline over 2 years of follow-up. Methods: 373 patients from a memory-clinic underwent BP measurements at baseline, year 1, and year 2. The mean of visit-to-visit systolic BP, diastolic BP, pulse pressure, and mean arterial pressure were calculated. Baseline and year 2 MRI scans were graded for WMH, infarcts, CMBs, intracranial stenosis, and hippocampal volume. Functional-cognitive decline was assessed using locally validated protocol. Logistic and linear regression models with odds ratios, mean difference, and 95%confidence interval were constructed to analyze associations of visit-to-visit BP on CeVD incidence and progression as well as functional-cognitive decline. Results: Higher mean of visit-to-visit diastolic BP was associated with WMH progression. Higher tertiles of diastolic BP was associated with WMH progression and incident CMBs. There was no association between mean of visit-to-visit BP measures with incident cerebral infarcts, intracranial stenosis, change in hippocampal volume, and functional-cognitive decline. Conclusion: These findings suggest the possibility of hypertension-related vascular brain damage. Careful monitoring and management of BP in elderly patients is essential to reduce the incidence and progression of CeVD.
- 1 July 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (7) , 2275-2283
Blood-Based Cardiac Biomarkers and the Risk of Cognitive Decline, Cerebrovascular Disease, and Clinical Events
Background and Purpose: Cardiac biomarkers, NT-proBNP (N-terminal probrain natriuretic peptide), hs-cTnT (high-sensitivity-cardiac troponin T), and GDF-15 (growth differentiation factor-15) have been proposed as important biomarkers of early vascular pathology. However, little is known of the longitudinal associations of these cardiac biomarkers with cerebrovascular disease and clinical events. We examine the association of blood-based cardiac biomarkers (NT-proBNP, hs-cTnT, and GDF-15) with cognitive decline, incident cerebrovascular disease, vascular events, and mortality. Methods: Four hundred thirty-four memory-clinic patients provided blood samples at baseline, underwent 3 annual neuropsychological assessments and brain magnetic resonance imaging scans at baseline and follow-up. NT-proBNP and hs-cTnT concentrations were measured by electrochemiluminescence immunoassay and GDF-15 by quantitative sandwich immunoassay. Baseline and follow-up magnetic resonance imagings were graded for white matter hyperintensities, lacunes, cerebral microbleeds, cortical infarcts, and intracranial stenosis. Data on incident vascular events and mortality were obtained. Results: Patients with higher levels of NT-proBNP, hs-cTnT, and GDF-15 showed greater decline in memory domain. Additionally, hs-cTnT was associated with decline in global cognition, executive function, and visuomotor speed. Higher levels of NT-proBNP were associated with incident cerebral microbleeds and hs-cTnT with incident cortical infarcts. During a mean follow-up of 3 years, 26 (5.9%) patients died and 35 (8.1%) developed vascular events. Patients with higher levels of NTpro-BNP and hs-cTnT were at increased risk of vascular events whereas those with higher levels of NT-proBNP and GDF-15 were at risk of mortality. Conclusions: Higher levels of blood-based cardiac biomarkers were associated with decline in memory and risk of vascular events and mortality. Moreover, NT-proBNP and hs-cTnT were associated with incident cerebral microbleeds and cortical infarcts. Thus, these biomarkers are potentially useful in identifying patients at risk of adverse vascular events and death.
- 1 July 2021
- Published by Wolters Kluwer Health in Stroke
- Vol. 52 (7) , 2275-2283
Blood-Based Cardiac Biomarkers and the Risk of Cognitive Decline, Cerebrovascular Disease, and Clinical Events
Background and Purpose: Cardiac biomarkers, NT-proBNP (N-terminal probrain natriuretic peptide), hs-cTnT (high-sensitivity-cardiac troponin T), and GDF-15 (growth differentiation factor-15) have been proposed as important biomarkers of early vascular pathology. However, little is known of the longitudinal associations of these cardiac biomarkers with cerebrovascular disease and clinical events. We examine the association of blood-based cardiac biomarkers (NT-proBNP, hs-cTnT, and GDF-15) with cognitive decline, incident cerebrovascular disease, vascular events, and mortality. Methods: Four hundred thirty-four memory-clinic patients provided blood samples at baseline, underwent 3 annual neuropsychological assessments and brain magnetic resonance imaging scans at baseline and follow-up. NT-proBNP and hs-cTnT concentrations were measured by electrochemiluminescence immunoassay and GDF-15 by quantitative sandwich immunoassay. Baseline and follow-up magnetic resonance imagings were graded for white matter hyperintensities, lacunes, cerebral microbleeds, cortical infarcts, and intracranial stenosis. Data on incident vascular events and mortality were obtained. Results: Patients with higher levels of NT-proBNP, hs-cTnT, and GDF-15 showed greater decline in memory domain. Additionally, hs-cTnT was associated with decline in global cognition, executive function, and visuomotor speed. Higher levels of NT-proBNP were associated with incident cerebral microbleeds and hs-cTnT with incident cortical infarcts. During a mean follow-up of 3 years, 26 (5.9%) patients died and 35 (8.1%) developed vascular events. Patients with higher levels of NTpro-BNP and hs-cTnT were at increased risk of vascular events whereas those with higher levels of NT-proBNP and GDF-15 were at risk of mortality. Conclusions: Higher levels of blood-based cardiac biomarkers were associated with decline in memory and risk of vascular events and mortality. Moreover, NT-proBNP and hs-cTnT were associated with incident cerebral microbleeds and cortical infarcts. Thus, these biomarkers are potentially useful in identifying patients at risk of adverse vascular events and death.